Back
Supernus Pharmaceuticals Quote, Financials, Valuation and Earnings
Will Crypto Make People Rich Again Starting April 2024?
Details on how to profit here.
Sell
38
SUPN
Supernus Pharmaceuticals
Last Price:
30.51
Seasonality Move:
12.2%
7 Day Trial
ALL ACCESS PASS
$
7
America's Final Republican President
Click here to see his 2024 election prediction.Supernus Pharmaceuticals Price Quote
$30.51
+0.24 (+0.79%)
(Updated: May 3, 2024 at 3:45 PM ET)
Supernus Pharmaceuticals Key Stats
Sell
38
Supernus Pharmaceuticals (SUPN)
is a Sell
Day range:
$29.79 - $30.66
52-week range:
$21.99 - $38.08
Dividend yield:
0%
P/E ratio:
1,513.50
P/S ratio:
2.83
P/B ratio:
1.8%
Volume:
266.8K
Avg. volume:
365.7K
1-year change:
-18.8%
Market cap:
$1.7B
Revenue:
$607.5M
EPS:
$-0
How Much Does Supernus Pharmaceuticals Make?
-
How Much Are Supernus Pharmaceuticals's Sales Annually?
SUPN Revenues are $607.5M -
How Much Profit Does Supernus Pharmaceuticals's Make A Year?
SUPN net income is $1.3M
Is Supernus Pharmaceuticals Growing As A Company?
-
What Is Supernus Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.02% -
What Is Supernus Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is -0.96%
Supernus Pharmaceuticals Stock Price Performance
-
Did Supernus Pharmaceuticals Stock Go Up Last Month?
Supernus Pharmaceuticals share price went down by -8.74% last month -
Did SUPN's Share Price Rise Over The Last Year?
SUPN share price fell by -18.8% over the past 1 year
What Is Supernus Pharmaceuticals 52-Week High & Low?
-
What Is Supernus Pharmaceuticals’s 52-Week High Share Price?
Supernus Pharmaceuticals has traded as high as $38.08 over the past 52 weeks -
What Is Supernus Pharmaceuticals’s 52-Week Low Share Price?
Supernus Pharmaceuticals has traded as low as $21.99 over the past 52 weeks
Supernus Pharmaceuticals Price To Free Cash Flow
-
Is Supernus Pharmaceuticals Stock Overvalued?
Supernus Pharmaceuticals is trading at a price to free cash flow ratio of 15.53 -
Is Supernus Pharmaceuticals Stock Undervalued?
Supernus Pharmaceuticals EV to Free Cash Flow ratio is 12.68 -
What Is Supernus Pharmaceuticals’s Price Earnings Growth Ratio?
SUPN PEG ratio is 0.00 -
Is Supernus Pharmaceuticals Trading At A Premium To Earnings?
Supernus Pharmaceuticals EV to EBIT ratio is 270.44
Is It Risky To Buy Supernus Pharmaceuticals?
-
How Much Debt Does Supernus Pharmaceuticals Have?
Total long term debt quarterly is $0 -
How Much Cash Does Supernus Pharmaceuticals Have?
Cash and short term investments quarterly total is $254.9M -
What Is Supernus Pharmaceuticals’s Book Value Per Share?
Book value per share is 16.84
Is Supernus Pharmaceuticals Cash Flow Positive?
-
What Is SUPN Cash Flow From Operations?
Cash flow from operations (TTM) is $111.1M -
What Is Supernus Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$397.9M -
What Is Supernus Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is $268.7M
Supernus Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
SUPN return on invested capital is 0.12% -
What Is Supernus Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is 0.09% -
What Is SUPN Return On Equity?
ROE is a measure of profitability and is 0.15%
Supernus Pharmaceuticals Earnings Date & Stock Price
-
What Is Supernus Pharmaceuticals's Stock Price Today?
A single share of SUPN can be purchased today for 30.27 -
What Is Supernus Pharmaceuticals’s Stock Symbol?
Supernus Pharmaceuticals trades on the nasdaq under the ticker symbol: SUPN -
When Is Supernus Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Supernus Pharmaceuticals is scheduled on May 8, 2024 -
When Is SUPN's next ex-dividend date?
Supernus Pharmaceuticals's next ex-dividend date is May 7, 2020 -
How To Buy Supernus Pharmaceuticals Stock?
You can buy Supernus Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Supernus Pharmaceuticals Competitors
-
Who Are Supernus Pharmaceuticals's Competitors?
Below is a list of companies who compete with Supernus Pharmaceuticals or are related in some way:
Supernus Pharmaceuticals Dividend Yield
Data Unavailable
Supernus Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | -95.95% | 61.03% |
| Revenue: | -1.8% | 5.99% |
Analyst Recommendations
| Buy Recommendations: | 2 |
|---|---|
| Hold Recommendations: | 1 |
| Sell Recommendations: | 0 |
| Price Target: | 40.33 |
| Upside from Last Price: | 33.25% |